Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER				PATIENT:			
Name	:			Name:			
Ward:				NHI:			
Dexr	azox	ane	•				
	INITIATION Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a medical oncologist, paediatric oncologist, haematologist or paediatric haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.						
	and or))	Patient is to receive treatment with high dose anthracycline given with curative intent Based on current treatment plan, patient's cumulative lifetime dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or greater Dexrazoxane to be administered only whilst on anthracycline treatment				
		or	Treatment to be used as a cardioprotectant for a child or Treatment to be used as a cardioprotectant for secondary.				

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	